PsychonautWiki Archive

Talk:Glaucine: Difference between revisions

← Older edit
>Blackhole
m 0xea moved page Glaucine to Talk:Glaucine: move to talk namespace
>AxeOvKindness
Grammatics
 
(22 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{decree|type=notice|message=This article is in the 'Talk' namespace because it is an unfinished draft. This section is used to host drafts for unpublished articles as well as discussions for published ones. If you'd like to use this area to discuss this draft, please do so in the 'Discussion' section at the very bottom of the page. This notice will be removed once this draft has been approved for publication by an administrator.}}
{{headerpanel|{{Approval}}}}
{{headerpanel|{{Approval}}}}
{{SummarySheet}}
{{SummarySheet}}
Glaucine is a naturally occurring novel [[psychedelic]] substance of the [[aporphine]] class found in ''[[Glaucium Flavum]]''.<ref>https://link.springer.com/article/10.1023/B:PHAC.0000048907.58847.c6</ref> Glaucine has one stereocenter, therefore it has two stereoisomers, where (S)-Glaucine is a 5-HT<sub>2A</sub>  [[agonist]] and (R)-Glaucine is a 5-HT<sub>2</sub> positive allosteric modulator.<ref name=":1">https://onlinelibrary.wiley.com/doi/10.1111/cbdd.13390</ref> Its psychedelic effects are believed to be produced by its interaction with [[serotonin]] [[Receptor|receptors]] like most psychedelics do, but also has clinically significant interactions at D1<ref>https://www.sciencedirect.com/science/article/abs/pii/S0968089605002312?via%3Dihub</ref> and α1<ref name=":2">https://pubmed.ncbi.nlm.nih.gov/30216681/</ref> receptors as an [[antagonist]], and inhibits MOA to a moderate degree.<ref>https://www.sciencedirect.com/science/article/abs/pii/S0021967319301104?via%3Dihub</ref> Glaucine has a close relative found in [[Blue Lotus]] (''Nymphaea nouchali)'' called [[apomorphine]]. It is both psychedelic as well as sedating, but the [[sedation]] is more similar to that of [[opioids]] than [[Psilocybin mushrooms|psilocybin]], a generally sedating psychedelic. It is most commonly consumed [[Routes of administration|orally]].
Glaucine is a naturally occurring novel [[psychedelic]] substance of the [[aporphine]] class found in ''[[Glaucium Flavum]]''.<ref>https://link.springer.com/article/10.1023/B:PHAC.0000048907.58847.c6</ref> Glaucine has one stereocenter, therefore it has two stereoisomers, where (S)-Glaucine is a 5-HT<sub>2A</sub>  [[agonist]] and (R)-Glaucine is a 5-HT<sub>2</sub> positive allosteric modulator.<ref name=":1">https://onlinelibrary.wiley.com/doi/10.1111/cbdd.13390</ref> Its psychedelic effects are believed to be produced by its interaction with [[serotonin]] [[Receptor|receptors]] like most psychedelics do, but also has clinically significant interactions at D1<ref>https://www.sciencedirect.com/science/article/abs/pii/S0968089605002312?via%3Dihub</ref> and α1<ref name=":2">https://pubmed.ncbi.nlm.nih.gov/30216681/</ref> receptors as an [[antagonist]], and inhibits MOA to a moderate degree.<ref>https://www.sciencedirect.com/science/article/abs/pii/S0021967319301104?via%3Dihub</ref> Glaucine has a close relative found in [[Blue Lotus]] (''Nymphaea nouchali)'' called [[apomorphine]]. It is both psychedelic as well as sedating, but the [[sedation]] is more similar to that of [[opioids]] than [[Psilocybin mushrooms|psilocybin]], a generally sedating psychedelic. It is most commonly consumed [[Routes of administration|orally]].


{{SubstanceBox
{{SubstanceBox/Glaucine}}
 
    <!-- Special Parameters -->
    |displayClasses={{{displayClasses|}}}
    |MaterialTable_MaxWidth=250px
    |MaterialTable_Title={{PAGENAME}}
 
    <!-- Modules -->
    |ModuleSource=false
    |ModuleCombination=false
    |ModuleStructure=true
    |ModuleNomenclature=true
    |ModuleClassMembership=true
    |ModuleROA=true
 
    <!-- Source -->
    |PhotoImageFile=
    |PhotoImageWidth=
    |PhotoImageCaption=
 
    <!-- Combination -->
    |CombinationImage1_Caption=
    |CombinationImage1_File=
    |CombinationImage1_Width=
 
    |CombinationImage2_Caption=
    |CombinationImage2_File=
    |CombinationImage2_Width=
 
    |CombinationImage3_Caption=
    |CombinationImage3_File=
    |CombinationImage3_Width=
 
    <!-- Structure -->
    |MolecularStructureCaption=Molecular structure of glaucine
    |SkeletalImageFile=File:Glaucine.svg
    |SkeletalImageWidth=245px
    |3DImageFile=
    |3DImageWidth=
 
    <!-- Nomenclature -->
    |NameCommon=Glaucine
    |NameSubstitution=1,2,9,10-tetramethoxy-aporphine
    |NameSystematic=(S)-1,2,9,10-tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline
 
    <!-- Class Membership -->
    |EffectClass=[[Psychoactive class::Psychedelic]] / [[Psychoactive class::Depressant]]
    |ChemicalClass=[[chemical class::Aporphine]]
 
    <!-- Dosage/Duration per ROA -->
 
    |OralROA=true
    |OralROA_Collapsed=false
    |OralROA_Caption=
    |OralROA_Bioavailability=[[Oral min bioavailability::17]]% - [[Oralmax bioavailability::48]]% <ref>https://pubmed.ncbi.nlm.nih.gov/35394081/#:~:text=Bioavailability%20following%20oral%20administration%20was,16%20and%2048%20h%2C%20respectively.</ref>
    |OralROA_Microdose=
    |OralROA_Threshold=[[Oral threshold dose::20]] [[Oral dose units::mg]]
    |OralROA_Light=[[Oral min light dose::20]] - [[Oral max light dose::75]] mg
    |OralROA_Common=[[Oral min common dose::75]] - [[Oral max common dose::150]] mg
    |OralROA_Strong=[[Oral min strong dose::150]] - [[Oral max strong dose::180]] mg
    |OralROA_Heavy=[[Oral heavy dose::180]] mg +
    |OralROA_TimelineFile=
    |OralROA_TimelineWidth=
    |OralROA_Duration=[[Oral min total time::3]] - [[Oral max total time::6]] [[Oral total time units::hours]]
    |OralROA_Onset=[[Oral min onset time::20]] - [[Oral max onset time::45]] [[Oral onset time units::minutes]]
    |OralROA_Comeup=[[Oral min comeup time::30]] - [[Oral max comeup time::60]] [[Oral comeup time units::minutes]]
    |OralROA_Peak=[[Oral min peak time::1]] - [[Oral max peak time::3]] [[Oral peak time units::hours]]
    |OralROA_Offset=[[Oral min offset time::1]] - [[Oral max offset time::2]] [[Oral offset time units::hours]]
    |OralROA_Aftereffects=[[Oral min afterglow time::3]] - [[Oral max afterglow time::8]] [[Oral afterglow time units::hours]]
 
    |SublingualROA=false
    |SublingualROA_Collapsed=true
    |SublingualROA_Caption=
    |SublingualROA_Bioavailability=[[Sublingual min bioavailability::x]]% - [[Sublingual max bioavailability::y]]%
    |SublingualROA_Microdose=
    |SublingualROA_Threshold=[[Sublingual threshold dose::x]] - [[Sublingual dose units::mg]]
    |SublingualROA_Light=[[Sublingual min light dose::x]] - [[Sublingual max light dose::y]] mg
    |SublingualROA_Common=[[Sublingual min common dose::x]] - [[Sublingual max common dose::y]] mg
    |SublingualROA_Strong=[[Sublingual min strong dose::x]] - [[Sublingual max strong dose::y]] mg
    |SublingualROA_Heavy=[[Sublingual heavy dose::x]] mg +
    |SublingualROA_TimelineFile=
    |SublingualROA_TimelineWidth=
    |SublingualROA_Duration=[[Sublingual min total time::a]] - [[Sublingual max total time::b]] [[Sublingual total time units::hours]]
    |SublingualROA_Onset=[[Sublingual min onset time::a]] - [[Sublingual max onset time::b]] [[Sublingual onset time units::minutes]]
    |SublingualROA_Comeup=[[Sublingual min comeup time::a]] - [[Sublingual max comeup time::b]] [[Sublingual comeup time units::minutes]]
    |SublingualROA_Peak=[[Sublingual min peak time::a]] - [[Sublingual max peak time::b]] [[Sublingual peak time units::hours]]
    |SublingualROA_Offset=[[Sublingual min offset time::a]] - [[Sublingual max offset time::b]] [[Sublingual offset time units::hours]]
    |SublingualROA_Aftereffects=[[Sublingual min afterglow time::a]] - [[Sublingual max afterglow time::b]] [[Sublingual afterglow time units::hours]]
 
    |BuccalROA=false
    |BuccalROA_Collapsed=True
    |BuccalROA_Caption=
    |BuccalROA_Bioavailability=[[Buccal min bioavailability::x]]% - [[Buccal max bioavailability::y]]%<ref>APA formatted citation</ref>
    |BuccalROA_Microdose=
    |BuccalROA_Threshold=[[Buccal threshold dose::x]] -  [[Buccal dose units::mg]]
    |BuccalROA_Light=[[Buccal min light dose::x]] - [[Buccal max light dose::y]] mg
    |BuccalROA_Common=[[Buccal min common dose::x]] - [[Buccal max common dose::y]] mg
    |BuccalROA_Strong=[[Buccal min strong dose::x]] - [[Buccal max strong dose::y]] mg
    |BuccalROA_Heavy=[[Buccal heavy dose::x]] mg +
    |BuccalROA_TimelineFile=
    |BuccalROA_TimelineWidth=
    |BuccalROA_Duration=[[Buccal min total time::x]] - [[Buccal max total time::y]] [[Buccal total time units::hours]]
    |BuccalROA_Onset=[[Buccal min onset time::x]] - [[Buccal max onset time::y]] [[Buccal onset time units::minutes]]
    |BuccalROA_Comeup=[[Buccal min comeup time::x]] - [[Buccal max comeup time::y]] [[Buccal comeup time units::minutes]]
    |BuccalROA_Peak=[[Buccal min peak time::x]] - [[Buccal max peak time::y]] [[Buccal peak time units::hours]]
    |BuccalROA_Offset=[[Buccal min offset time::x]] - [[Buccal max offset time::y]] [[Buccal offset time units::hours]]
    |BuccalROA_Aftereffects=[[Buccal min afterglow time::x]] - [[Buccal max afterglow time::y]] [[Buccal afterglow time units::hours]]
 
    |InsufflatedROA=false
    |InsufflatedROA_Collapsed=True
    |InsufflatedROA_Caption=
    |InsufflatedROA_Bioavailability=
    |InsufflatedROA_Microdose=
    |InsufflatedROA_Threshold=[[Insufflated threshold dose::5]] [[Insufflated dose units::mg]]
    |InsufflatedROA_Light=[[Insufflated min light dose::5]] - [[Insufflated max light dose::15]] mg
    |InsufflatedROA_Common=[[Insufflated min common dose::15]] - [[Insufflated max common dose::40]] mg
    |InsufflatedROA_Strong=[[Insufflated min strong dose::40]] - [[Insufflated max strong dose::80]] mg
    |InsufflatedROA_Heavy=[[Insufflated heavy dose::80]] mg +
    |InsufflatedROA_TimelineFile=
    |InsufflatedROA_TimelineWidth=
    |InsufflatedROA_Duration=[[Insufflated min total time::2]] - [[Insufflated max total time::4]] [[Insufflated total time units::hours]]
    |InsufflatedROA_Onset=[[Insufflated min onset time::10]] - [[Insufflated max onset time::15]] [[Insufflated onset time units::minutes]]
    |InsufflatedROA_Comeup=
    |InsufflatedROA_Peak=[[Insufflated min peak time::1]] - [[Insufflated max peak time::1.5]] [[Insufflated peak time units::hours]]
    |InsufflatedROA_Offset=[[Insufflated min offset time::1]] - [[Insufflated max offset time::2]] [[Insufflated offset time units::hours]]
    |InsufflatedROA_Aftereffects=[[Insufflated min afterglow time::1]] - [[Insufflated max afterglow time::1.5]] [[Insufflated afterglow time units::hours]]
 
    |RectalROA=false
    |RectalROA_Collapsed=True
    |RectalROA_Caption=
    |RectalROA_Bioavailability=[[Rectal min bioavailability::x]]% - [[Rectal max bioavailability::y]]
    |RectalROA_Microdose=
    |RectalROA_Threshold=[[Rectal threshold dose::x]] -  [[Rectal dose units::mg]]
    |RectalROA_Light=[[Rectal min light dose::x]] - [[Rectal max light dose::y]] mg
    |RectalROA_Common=[[Rectal min common dose::x]] - [[Rectal max common dose::y]] mg
    |RectalROA_Strong=[[Rectal min strong dose::x]] - [[Rectal max strong dose::y]] mg
    |RectalROA_Heavy=[[Rectal heavy dose::x]] mg +
    |RectalROA_TimelineFile=
    |RectalROA_TimelineWidth=
    |RectalROA_Duration=[[Rectal min total time::x]] - [[Rectal max total time::y]] [[Rectal total time units::hours]]
    |RectalROA_Onset=[[Rectal min onset time::x]] - [[Rectal max onset time::y]] [[Rectal onset time units::minutes]]
    |RectalROA_Comeup=[[Rectal min comeup time::x]] - [[Rectal max comeup time::y]] [[Rectal comeup time units::minutes]]
    |RectalROA_Peak=[[Rectal min peak time::x]] - [[Rectal max peak time::y]] [[Rectal peak time units::hours]]
    |RectalROA_Offset=[[Rectal min offset time::x]] - [[Rectal max offset time::y]] [[Rectal offset time units::hours]]
    |RectalROA_Aftereffects=[[Rectal min afterglow time::x]] - [[Rectal max afterglow time::y]] [[Rectal afterglow time units::hours]]
 
    |TransdermalROA=false
    |TransdermalROA_Collapsed=True
    |TransdermalROA_Caption=
    |TransdermalROA_Bioavailability=[[Transdermal min bioavailability::x]]% - [[Transdermal max bioavailability::y]]%<ref>APA formatted citation</ref>
    |TransdermalROA_Microdose=
    |TransdermalROA_Threshold=[[Transdermal threshold dose::x]] -  [[Transdermal dose units::mg]]
    |TransdermalROA_Light=[[Transdermal min light dose::x]] - [[Transdermal max light dose::y]] mg
    |TransdermalROA_Common=[[Transdermal min common dose::x]] - [[Transdermal max common dose::y]] mg
    |TransdermalROA_Strong=[[Transdermal min strong dose::x]] - [[Transdermal max strong dose::y]] mg
    |TransdermalROA_Heavy=[[Transdermal heavy dose::x]] mg +
    |TransdermalROA_TimelineFile=
    |TransdermalROA_TimelineWidth=
    |TransdermalROA_Duration=[[Transdermal min total time::x]] - [[Transdermal max total time::y]] [[Transdermal total time units::hours]]
    |TransdermalROA_Onset=[[Transdermal min onset time::x]] - [[Transdermal max onset time::y]] [[Transdermal onset time units::minutes]]
    |TransdermalROA_Comeup=[[Transdermal min comeup time::x]] - [[Transdermal max comeup time::y]] [[Transdermal comeup time units::minutes]]
    |TransdermalROA_Peak=[[Transdermal min peak time::x]] - [[Transdermal max peak time::y]] [[Transdermal peak time units::hours]]
    |TransdermalROA_Offset=[[Transdermal min offset time::x]] - [[Transdermal max offset time::y]] [[Transdermal offset time units::hours]]
    |TransdermalROA_Aftereffects=[[Transdermal min afterglow time::x]] - [[Transdermal max afterglow time::y]] [[Transdermal afterglow time units::hours]]
 
    |SubcutaneousROA=false
    |SubcutaneousROA_Collapsed=True
    |SubcutaneousROA_Caption=
    |SubcutaneousROA_Bioavailability=[[Subcutaneous min bioavailability::x]]% - [[Subcutaneous max bioavailability::y]]%<ref>APA formatted citation</ref>
    |SubcutaneousROA_Microdose=
    |SubcutaneousROA_Threshold=[[Subcutaneous threshold dose::x]] -  [[Subcutaneous dose units::mg]]
    |SubcutaneousROA_Light=[[Subcutaneous min light dose::x]] - [[Subcutaneous max light dose::y]] mg
    |SubcutaneousROA_Common=[[Subcutaneous min common dose::x]] - [[Subcutaneous max common dose::y]] mg
    |SubcutaneousROA_Strong=[[Subcutaneous min strong dose::x]] - [[Subcutaneous max strong dose::y]] mg
    |SubcutaneousROA_Heavy=[[Subcutaneous heavy dose::x]] mg +
    |SubcutaneousROA_TimelineFile=
    |SubcutaneousROA_TimelineWidth=
    |SubcutaneousROA_Duration=[[Subcutaneous min total time::x]] - [[Subcutaneous max total time::y]] [[Subcutaneous total time units::hours]]
    |SubcutaneousROA_Onset=[[Subcutaneous min onset time::x]] - [[Subcutaneous max onset time::y]] [[Subcutaneous onset time units::minutes]]
    |SubcutaneousROA_Comeup=[[Subcutaneous min comeup time::x]] - [[Subcutaneous max comeup time::y]] [[Subcutaneous comeup time units::minutes]]
    |SubcutaneousROA_Peak=[[Subcutaneous min peak time::x]] - [[Subcutaneous max peak time::y]] [[Subcutaneous peak time units::hours]]
    |SubcutaneousROA_Offset=[[Subcutaneous min offset time::x]] - [[Subcutaneous max offset time::y]] [[Subcutaneous offset time units::hours]]
    |SubcutaneousROA_Aftereffects=[[Subcutaneous min afterglow time::x]] - [[Subcutaneous max afterglow time::y]] [[Subcutaneous afterglow time units::hours]]
 
    |IntramuscularROA=false
    |IntramuscularROA_Collapsed=true
    |IntramuscularROA_Caption=
    |IntramuscularROA_Bioavailability=[[Intramuscular min bioavailability::x]]% - [[Intramuscular max bioavailability::y]]%<ref>APA formatted citation</ref>
    |IntramuscularROA_Microdose=
    |IntramuscularROA_Threshold=[[Intramuscular threshold dose::x]] -  [[Intramuscular dose units::mg]]
    |IntramuscularROA_Light=[[Intramuscular min light dose::x]] - [[Intramuscular max light dose::y]] mg
    |IntramuscularROA_Common=[[Intramuscular min common dose::x]] - [[Intramuscular max common dose::y]] mg
    |IntramuscularROA_Strong=[[Intramuscular min strong dose::x]] - [[Intramuscular max strong dose::y]] mg
    |IntramuscularROA_Heavy=[[Intramuscular heavy dose::x]] mg +
    |IntramuscularROA_TimelineFile=
    |IntramuscularROA_TimelineWidth=
    |IntramuscularROA_Duration=[[Intramuscular min total time::x]] - [[Intramuscular max total time::y]] [[Intramuscular total time units::hours]]
    |IntramuscularROA_Onset=[[Intramuscular min onset time::x]] - [[Intramuscular max onset time::y]] [[Intramuscular onset time units::minutes]]
    |IntramuscularROA_Comeup=[[Intramuscular min comeup time::x]] - [[Intramuscular max comeup time::y]] [[Intramuscular comeup time units::minutes]]
    |IntramuscularROA_Peak=[[Intramuscular min peak time::x]] - [[Intramuscular max peak time::y]] [[Intramuscular peak time units::hours]]
    |IntramuscularROA_Offset=[[Intramuscular min offset time::x]] - [[Intramuscular max offset time::y]] [[Intramuscular offset time units::hours]]
    |IntramuscularROA_Aftereffects=[[Intramuscular min afterglow time::x]] - [[Intramuscular max afterglow time::y]] [[Intramuscular afterglow time units::hours]]
 
    |IntravenousROA=false
    |IntravenousROA_Collapsed=true
    |IntravenousROA_Caption=
    |IntravenousROA_Bioavailability=[[Intravenous min bioavailability::x]]% - [[Intravenous max bioavailability::y]]%<ref>APA formatted citation</ref>
    |IntravenousROA_Microdose=
    |IntravenousROA_Threshold=[[Intravenous threshold dose::x]] -  [[Intravenous dose units::mg]]
    |IntravenousROA_Light=[[Intravenous min light dose::x]] - [[Intravenous max light dose::y]] mg
    |IntravenousROA_Common=[[Intravenous min common dose::x]] - [[Intravenous max common dose::y]] mg
    |IntravenousROA_Strong=[[Intravenous min strong dose::x]] - [[Intravenous max strong dose::y]] mg
    |IntravenousROA_Heavy=[[Intravenous heavy dose::x]] mg +
    |IntravenousROA_TimelineFile=
    |IntravenousROA_TimelineWidth=
    |IntravenousROA_Duration=[[Intravenous min total time::x]] - [[Intravenous max total time::y]] [[Intravenous total time units::hours]]
    |IntravenousROA_Onset=[[Intravenous min onset time::x]] - [[Intravenous max onset time::y]] [[Intravenous onset time units::minutes]]
    |IntravenousROA_Comeup=[[Intravenous min comeup time::x]] - [[Intravenous max comeup time::y]] [[Intravenous comeup time units::minutes]]
    |IntravenousROA_Peak=[[Intravenous min peak time::x]] - [[Intravenous max peak time::y]] [[Intravenous peak time units::hours]]
    |IntravenousROA_Offset=[[Intravenous min offset time::x]] - [[Intravenous max offset time::y]] [[Intravenous offset time units::hours]]
    |IntravenousROA_Aftereffects=[[Intravenous min afterglow time::x]] - [[Intravenous max afterglow time::y]] [[Intravenous afterglow time units::hours]]
 
}}


Glaucine is rarely sold on the streets and almost exclusively distributed as a legal alternative to more common psychedelics, where it is commonly used for recreational and entheogenic purposes. It was and still is a very uncommon and unheard of substance with sparing experiences on the internet.
Glaucine is rarely sold on the streets and almost exclusively distributed as a legal alternative to more common psychedelics, where it is commonly used for recreational and entheogenic purposes. It was and still is a very uncommon and unheard of substance with sparing experiences on the internet.
Line 258: Line 35:
*'''[[Effect::Muscle relaxation]]'''
*'''[[Effect::Muscle relaxation]]'''
*'''[[Effect::Perception of bodily heaviness]]'''
*'''[[Effect::Perception of bodily heaviness]]'''
*'''[[Effect::Phsycial euphoria]]''' - It is usually felt as a warm encompassment of the body.
*'''[[Effect::Physical euphoria]]''' - It is usually felt as a warm encompassment of the body.
*'''[[Effect::Pupil dilation]]''' - Serotonergic substances are known to cause pupil dilation.
*'''[[Effect::Pupil dilation]]''' - Serotonergic substances are known to cause pupil dilation.


Line 266: Line 43:


====Enhancements====
====Enhancements====
*'''[[Effect::Pattern recognition enhancment]]'''
*'''[[Effect::Pattern recognition enhancement]]'''
 
====Distortions====
*'''[[Effect::Visual distortion effect1]]'''
 
====[[Effect::Geometry]]====
If applicable, a brief paragraph summary describing the visual geometry produced by the substance may be included here.
====Hallucinatory states====
If applicable, a brief summary of the substance's visual effects profile may be written here.
 
*'''[[Effect::Hallucinatory states1]]'''
 
}}
 
|{{effects/cognitive|
If applicable, a brief paragraph summary of the substance's cognitive effects may be included here.
 
You may select from a list of cognitive effects to add below [[Subjective effect index#Cognitive effects|here]].
 
*'''[[Effect::Cognitive effect1]]'''
*'''[[Effect::Cognitive effect2]]'''
*'''[[Effect::Cognitive effect3]]'''
 
}}
{{effects/auditory|
If applicable, a brief paragraph summary of the substance's auditory effects may be included here.
 
You may select from a list of auditory effects to add below [[Subjective effect index#Auditory effects|here]].
 
*'''[[Effect::Auditory effect1]]'''
*'''[[Effect::Auditory effect2]]'''
 
}}
{{effects/multisensory|
If applicable, a brief paragraph summary of the substance's multisensory effects may be included here.
 
You may select from a list of multisensory effects to add below [[Subjective effect index#Multisensory effects|here]].
 
*'''[[Effect::Multisensory effect1]]'''
*'''[[Effect::Multisensory effect2]]'''
 
}}
{{effects/transpersonal|
If applicable, a brief paragraph summary of the substance's transpersonal effects may be included here.
 
You may select from a list of transpersonal effects to add below [[Subjective effect index#Transpersonal effects|here]].
 
*'''[[Effect::Transpersonal effect1]]'''
*'''[[Effect::Transpersonal effect2]]'''


}}
}}
}}
}}
===Experience reports===
===Experience reports===
There are currently {{#ask:[[Category:SUBSTANCE]][[Category:Experience]] | format=count}} experience reports which describe the effects of this substance in our [[experience index]]. Additional experience reports can be found here:
There are currently {{#ask:[[Category:Glaucine]][[Category:Experience]] | format=count}} experience reports which describe the effects of this substance in our [[experience index]]. Additional experience reports can be found here:


*[https://www.erowid.org/experiences/subs/exp_Glaucine.shtml Erowid Experience Vaults: Glaucine]
*[https://www.erowid.org/experiences/subs/exp_Glaucine.shtml Erowid Experience Vaults: Glaucine]
Line 334: Line 63:
===Dangerous interactions===
===Dangerous interactions===


{{DangerousInteractions}}
{{DangerousInteractions/Intro}}
*'''Lithium''': Lithium is commonly prescribed in the treatment of bipolar disorder; however, there is a large body of anecdotal evidence that suggests taking it with psychedelics can significantly increase the risk of [[psychosis]] and [[seizures]]. As a result, this combination should be '''strictly avoided.'''
*'''Lithium''': Lithium is commonly prescribed in the treatment of bipolar disorder; however, there is a large body of anecdotal evidence that suggests taking it with psychedelics can significantly increase the risk of [[psychosis]] and [[seizures]]. As a result, this combination should be '''strictly avoided.'''
*'''[[Tramadol]]''': Tramadol is well documented to lower the seizure threshold in individuals and psychedelics also has the potential to induce seizures in susceptible individuals.<ref>https://www.sciencedirect.com/science/article/pii/S0376871622003234?via%3Dihub</ref>
*'''[[Tramadol]]''': Tramadol is well documented to lower the seizure threshold in individuals and psychedelics also has the potential to induce seizures in susceptible individuals.<ref>https://www.sciencedirect.com/science/article/pii/S0376871622003234?via%3Dihub</ref>
Line 341: Line 72:
*'''[[Stimulants]]''': (e.g. [[Amphetamine|'''''amphetamine''''']], [[Project talk:Methcathinone|'''''methcathinone''''']]): Due to a moderate inhibition of MAO-B, stimulants in combination with glaucine will cause a massive spike in blood pressure leading to hypertensive crisis as well as prolonged and more intense effects of stimulants. This combination should be '''strictly avoided.'''
*'''[[Stimulants]]''': (e.g. [[Amphetamine|'''''amphetamine''''']], [[Project talk:Methcathinone|'''''methcathinone''''']]): Due to a moderate inhibition of MAO-B, stimulants in combination with glaucine will cause a massive spike in blood pressure leading to hypertensive crisis as well as prolonged and more intense effects of stimulants. This combination should be '''strictly avoided.'''
*'''Tyramine''': Any food with a high level of tyramine should be avoided for two weeks after use. MAO-B inhibition can lead to a buildup of tyramine in the body, leading to a hypertensive crisis.
*'''Tyramine''': Any food with a high level of tyramine should be avoided for two weeks after use. MAO-B inhibition can lead to a buildup of tyramine in the body, leading to a hypertensive crisis.
{{DangerousInteractions}}
{{DangerousInteractions/Intro}}


==Legal status==
==Legal status==
Line 352: Line 81:


==External links==
==External links==
(List along order below)
*[https://en.wikipedia.org/wiki/SUBSTANCE SUBSTANCE (Wikipedia)]
*SUBSTANCE (Erowid Vault)
*SUBSTANCE ([''PiHKAL'' or ''TiHKAL''] / Isomer Design)
==Literature==
*APA formatted reference


Please see the [[citation formatting guide]] if you need assistance properly formatting citations.
*[https://en.wikipedia.org/wiki/Glaucine Glaucine (Wikipedia)]


==References==
==References==
Retrieved from "https://psy.st/wiki/Talk:Glaucine"
Return to "Glaucine" page.